Skip to main content

Articles

Page 1 of 42

  1. Relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD) represents a challenging condition, with limited treatment options and poor prognosis. We conducted a phase 1 clinical trial to eva...

    Authors: Hao Yao, Shi-hui Ren, Lin-hui Wang, Ming-qiang Ren, Jiao Cai, Dan Chen, Ying He, Si-han Lai, Bai-tao Dou, Meng-jiao Li, Yan-ling Li, Ya-li Cen, Alex H. Chang, Yi Su, Ling Qiu and Fang-yi Fan
    Citation: Journal of Hematology & Oncology 2025 18:56
    Content type: Correspondence Published on:

  2. Several studies have suggested that chemotherapy-free regimens consisting of blinatumomab and a BCR::ABL1 tyrosine kinase inhibitor are highly effective in Philadelphia chromosome-positive acute lymphoblastic ...

    Authors: Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar, Sanam Loghavi, Lewis Nasr, Fadi G. Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi and Elias Jabbour
    Citation: Journal of Hematology & Oncology 2025 18:55
    Content type: Research Published on:

  3. Although multiple myeloma (MM) remains an incurable disease, the advancements in patient management are rapid and novel approaches emerge each year. At the last congress of the American Society of Hematology (...

    Authors: Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis and Maria Gavriatopoulou
    Citation: Journal of Hematology & Oncology 2025 18:54
    Content type: Correspondence Published on:

  4. Approximately 78.3% of patients with t(8;21) acute myeloid leukemia (AML) express CD19, making it a potential target for chimeric antigen receptor (CAR)-T cell therapy focused on CD19. This prospective phase I...

    Authors: Jia Yin, Qing-Ya Cui, Hai-Ping Dai, Chang-Ju Qu, Zheng Li, Li-Qing Kang, Wei Cui, Xiao-Peng Tian, Xia-Ming Zhu, Lei Yu, De-Pei Wu and Xiao-Wen Tang
    Citation: Journal of Hematology & Oncology 2025 18:53
    Content type: Correspondence Published on:

  5. Selective elimination of proteins associated with the pathogenesis of diseases is an emerging therapeutic modality with distinct advantages over traditional inhibitor-based approaches. This strategy, called ta...

    Authors: M. A. A. Mamun, Anush G. Bakunts and Alexander L. Chernorudskiy
    Citation: Journal of Hematology & Oncology 2025 18:52
    Content type: Review Published on:

  6. Antibody–drug conjugates (ADCs) represent a novel class of biopharmaceuticals comprising monoclonal antibodies covalently conjugated to cytotoxic agents via engineered chemical linkers. This combination enable...

    Authors: Ruili Wang, Baohui Hu, Ziyu Pan, Chongxia Mo, Xin Zhao, Guojia Liu, Ping Hou, Qi Cui, Zhao Xu, Wenjia Wang, Zhaojin Yu, Lin Zhao, Miao He, Yan Wang, Chen Fu, Minjie Wei…
    Citation: Journal of Hematology & Oncology 2025 18:51
    Content type: Review Published on:

  7. Peripheral T-cell lymphoma (PTCL) is an aggressive malignancy with limited treatment options and poor prognosis, particularly for relapsed or refractory (r/r) patients. HH2853, a novel dual inhibitor of EZH1/2...

    Authors: Huangming Hong, Zegeng Chen, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He…
    Citation: Journal of Hematology & Oncology 2025 18:50
    Content type: Research Published on:

  9. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation has significantly improved overall survival (OS) in primary central nervous system lymphoma (PCNSL). However, early identif...

    Authors: Vanja Zeremski, Tobias R. Haage, Hanno M. Witte, Louisa Adolph, Sina A. Beer, Gerhard Behre, Benedikt Jacobs, Christoph Kahl, Chrysavgi Lalayanni, Jens Panse, Sotirios Papageorgiou, Marina P. Siakantaris, Jessica Schneider, Ulf Schnetzke, Alexander Schulz, Theodoros P. Vassilakopoulos…
    Citation: Journal of Hematology & Oncology 2025 18:48
    Content type: Correspondence Published on:

  10. Extramedullary disease (EMD) in multiple myeloma (MM) represents a significant clinical challenge, with a limited understanding of the spatial architecture and its pathobiological impact. To address this unmet...

    Authors: Vanessa Desantis, Alessandro Andriano, Tim Düking, Olga Hartwig, Giuseppe Ingravallo, Marta Biondo, Cirino Botta, Roberto Ria, Angelo Vacca and Antonio Giovanni Solimando
    Citation: Journal of Hematology & Oncology 2025 18:47
    Content type: Correspondence Published on:

  11. Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. No...

    Authors: V. Tomarchio, L. Rigacci and O. Annibali
    Citation: Journal of Hematology & Oncology 2025 18:46
    Content type: Correspondence Published on:

  12. In situ vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy, offering a targeted approach that uses the tumor microenvironment (TME) to stimulate an immune response directly at the tu...

    Authors: Naimeng Liu, Xiangyu Wang, Zhongzhao Wang, Yonemori Kan, Yi Fang, Jidong Gao, Xiangyi Kong and Jing Wang
    Citation: Journal of Hematology & Oncology 2025 18:45
    Content type: Review Published on:

  13. The clinical utility of liquid biopsy (LB) for pancreatic ductal adenocarcinoma (PDAC) remain understudied. Our single-institution cohort of 311 PDAC patients with non-tumor tissues informed LB found 81.2% pos...

    Authors: Mahmoud Yousef, Abdelrahman Yousef, Mark W. Hurd, Ashwathy Pillai, Saikat Chowdhury, Rebecca Snyder, Mark Knafl, Ryan L. Lewis, Paul M. Roy, Mohammad Fanaeian, Sali Albarouki, Luca F. Castelnovo, Jennifer Peterson, Brandon G. Smaglo, Robert A. Wolff, Shubham Pant…
    Citation: Journal of Hematology & Oncology 2025 18:44
    Content type: Correspondence Published on:

  14. Replicon RNA (RepRNA) represents a cutting-edge technology in the field of vaccinology, fundamentally transforming vaccine design and development. This innovative approach facilitates the induction of robust i...

    Authors: Lirui Tang, Haiying Que, Yuquan Wei, Ting Yang, Aiping Tong and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2025 18:43
    Content type: Review Published on:

  15. Gastric cancer is the fifth most common cancer globally and is associated with significant morbidity and mortality. Despite its alarming prevalence, limited comparative evidence exists on its treatment efficac...

    Authors: Yang Chen, Keren Jia, Yi Xie, Jiajia Yuan, Dan Liu, Lei Jiang, Haoxin Peng, Jia Zhong, Jian Li, Xiaotian Zhang and Lin Shen
    Citation: Journal of Hematology & Oncology 2025 18:42
    Content type: Research Published on:

  16. Recent research from our group has shown that the overexpression of the wild-type RAS-family GTPase RRAS2 drives the onset of triple-negative breast cancer (TNBC) in mice following one or more pregnancies. This p...

    Authors: Claudia Cifuentes, Lydia Horndler, Pilar Grosso, Clara L Oeste, Alejandro M. Hortal, Jennifer Castillo, Isabel Fernández-Pisonero, Alberto Paradela, Xosé Bustelo and Balbino Alarcón
    Citation: Journal of Hematology & Oncology 2025 18:41
    Content type: Research Published on:

  17. Innate immunity represents the body’s first line of defense, effectively countering the invasion of external pathogens. Recent studies have highlighted the crucial role of innate immunity in antitumor defense,...

    Authors: Mengzhou Shen, Xianjie Jiang, Qiu Peng, Linda Oyang, Zongyao Ren, Jiewen Wang, Mingjing Peng, Yujuan Zhou, Xiyun Deng and Qianjin Liao
    Citation: Journal of Hematology & Oncology 2025 18:40
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2025 18:49

  18. Identifying robust diagnostic biomarkers for gastric cancer (GC) remains a significant challenge. Emerging studies highlight extracellular vesicle (EV)-derived RNAs in cancer biology, but the diagnostic potent...

    Authors: Ping Yang, Zhibo Li, Xi Chen, Chiyuan Ma, Yiyuan Han, Xiaoshan Zhang, Xiaodong Wei, Yueyue Lei, Tonghui Ma and Fangfang Jin
    Citation: Journal of Hematology & Oncology 2025 18:39
    Content type: Correspondence Published on:

  19. C3G, a Rap1 GEF, promotes megakaryopoiesis and platelet function. Using transgenic and knock-out mouse models targeting C3G in megakaryocytes, we investigated whether C3G also affects the niche function of meg...

    Authors: Óscar Herranz, Pablo Berrocal, Carmen Sicilia-Navarro, Cristina Fernández-Infante, Luis Hernández-Cano, Almudena Porras and Carmen Guerrero
    Citation: Journal of Hematology & Oncology 2025 18:38
    Content type: Research Published on:

  20. Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation and high metastatic potential. It is characterized by universal inactivation of and RB1, overexpression of the MYC...

    Authors: Xiaoqian Zhai, Zhengkun Zhang, Yuxin Chen, Yanmou Wu, Cheng Zhen, Yu Liu, Yiyun Lin and Chong Chen
    Citation: Journal of Hematology & Oncology 2025 18:37
    Content type: Review Published on:

  21. Cancer-associated fibroblasts (CAFs) are key players in cancer development and therapy, and they exhibit multifaceted roles in the tumor microenvironment (TME). From their diverse cellular origins, CAFs underg...

    Authors: Hongyuan Jia, Xingmin Chen, Linling Zhang and Meihua Chen
    Citation: Journal of Hematology & Oncology 2025 18:36
    Content type: Review Published on:

  22. The development of targeted therapy with small-molecule tyrosine kinase inhibitors and immunotherapy with immune checkpoints inhibitors has ushered in the era of precision medicine in treating lung cancer, whi...

    Authors: Po-Lan Su, Naoki Furuya, Alahmadi Asrar, Christian Rolfo, Zihai Li, David P. Carbone and Kai He
    Citation: Journal of Hematology & Oncology 2025 18:35
    Content type: Review Published on:

  23. Authors: Zwi N. Berneman, Maxime De Laere, Paul Germonpré, Manon T. Huizing, Yannick Willemen, Eva Lion, Hans De Reu, Jolien Van den Bossche, Jan Van den Brande, Pol Specenier, Sevilay Altintas, Peter A. van Dam, Nathalie Cools, Griet Nijs, Barbara Stein, Kim Caluwaerts…
    Citation: Journal of Hematology & Oncology 2025 18:34
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2025 18:9

  24. Ovarian epithelial cancer (OEC), particularly high-grade serous carcinoma (HGSC), remains a clinical challenge due to its late-stage diagnosis, high recurrence rates, and poor survival outcomes. Mirvetuximab s...

    Authors: Beihua Kong and Wenxin Zheng
    Citation: Journal of Hematology & Oncology 2025 18:33
    Content type: Editorial Published on:

  25. In the domain of addressing cancer resistance, challenges such as limited effectiveness and treatment resistance remain persistent. Hypoxia is a key feature of solid tumors and is strongly associated with poor...

    Authors: Tongxuan Shang, Ziqi Jia, Jiayi Li, Heng Cao, Hengyi Xu, Lin Cong, Dongxu Ma, Xiang Wang and Jiaqi Liu
    Citation: Journal of Hematology & Oncology 2025 18:32
    Content type: Review Published on:

  26. Authors: Hongsheng Fang, Weixing Dai, Ruiqi Gu, Yanbo Zhang, Jin Li, Wenqin Luo, Shanyou Tong, Lingyu Han, Yichao Wang, Chengyao Jiang, Xue Wang, Renjie Wang and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2025 18:31
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2024 17:126

  27. Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While ...

    Authors: Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma, Don Benson, Francesca Cottini, Evandro Bezerra, Jonathan Brammer, Naresh Bumma, Hannah Choe, Nathan Denlinger, Srinivas Devarakonda, Abdullah Khan, Sam Penza, Ashley Rosko…
    Citation: Journal of Hematology & Oncology 2025 18:30
    Content type: Correspondence Published on:

  28. Lymphoma, a malignant tumor derived from lymphocytes and lymphoid tissues, presents with complex and heterogeneous clinical manifestations, requiring accurate patient classification for appropriate treatment. ...

    Authors: Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu and Xiaoxue Wang
    Citation: Journal of Hematology & Oncology 2025 18:29
    Content type: Review Published on:

  29. Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to ac...

    Authors: Qiling Bu, Hong-Hu Zhu and Wenming Chen
    Citation: Journal of Hematology & Oncology 2025 18:28
    Content type: Correspondence Published on:

  30. Pancreatic cancer is one of the most malignant cancers, and limited therapeutic options are available. The induction of ferroptosis is considered to be a novel, promising strategy that has potential in cancer ...

    Authors: Yahui Ding, Yongping Bai, Tianyang Chen, Sisi Chen, Wanjing Feng, Shuoqian Ma and Quan Zhang
    Citation: Journal of Hematology & Oncology 2025 18:27
    Content type: Research Published on:

  31. Degrader therapies have garnered significant attention for their innovative approach to targeting and eliminating malignancy-associated proteins, holding promise for improving outcomes for patients with relaps...

    Authors: Na Li, Jianpeng Sheng and Hong-Hu Zhu
    Citation: Journal of Hematology & Oncology 2025 18:26
    Content type: Correspondence Published on:

  33. Despite the success of immune checkpoint inhibitors (ICIs) in multiple malignant tumors, a significant proportion of patients remain unresponsive to treatment. Radiotherapy (RT) elicits immunogenic antitumor r...

    Authors: Yuze Wu, Yuheng Yan, Yarong Guo, Mengke Niu, Binghan Zhou, Jing Zhang, Pengfei Zhou, Qian Chu, Qi Mei, Ming Yi and Kongming Wu
    Citation: Journal of Hematology & Oncology 2025 18:24
    Content type: Research Published on:

  34. B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chime...

    Authors: Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu and Zhenshu Xu
    Citation: Journal of Hematology & Oncology 2025 18:23
    Content type: Correspondence Published on:

  35. Natural killer cells, integral to the innate immune response, exhibit the inherent capacity to identify and eliminate cancer cells without prior exposure, positioning them as prime candidates for immunotherape...

    Authors: Ran Kong, Bingyu Liu, Hua Wang, Tiange Lu and Xiangxiang Zhou
    Citation: Journal of Hematology & Oncology 2025 18:22
    Content type: Correspondence Published on:

  36. Authors: Le Qin, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Yangqiu Li, Xuchao Zhang, Yilong Wu, Pentao Liu, Yao Yao…
    Citation: Journal of Hematology & Oncology 2025 18:21
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:68

  37. In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encoded by ncRNAs representing a particularly promising avenue of investigation. The identif...

    Authors: Shiming Tan, Wenjuan Yang, Zongyao Ren, Qiu Peng, Xuemeng Xu, Xianjie Jiang, Zhu Wu, Linda Oyang, Xia Luo, Jinguan Lin, Longzheng Xia, Mingjing Peng, Nayiyuan Wu, Yanyan Tang, Yaqian Han, Qianjin Liao…
    Citation: Journal of Hematology & Oncology 2025 18:20
    Content type: Review Published on:

  39. Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered sign...

    Authors: Yingqiong Zhou, Yuquan Wei, Xiaohe Tian and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2025 18:18
    Content type: Review Published on:

  40. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer.

    Authors: Roman M. Shapiro, Michal Sheffer, Matthew A. Booker, Michael Y. Tolstorukov, Grace C. Birch, Moshe Sade-Feldman, Jacy Fang, Shuqiang Li, Wesley Lu, Michela Ansuinelli, Remy Dulery, Mubin Tarannum, Joanna Baginska, Nishant Dwivedi, Ashish Kothari, Livius Penter…
    Citation: Journal of Hematology & Oncology 2025 18:17
    Content type: Research Published on:

  41. Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may be beneficial for cancer treatment. Herein we first report on the anticancer activity ...

    Authors: HyunJun Kang, Dinh Hoa Hoang, Melissa Valerio, Khyatiben Pathak, William Graff, Alexis LeVee, Jun Wu, Mark A. LaBarge, David Frankhouser, Russell C. Rockne, Patrick Pirrotte, Bin Zhang, Joanne Mortimer, Le Xuan Truong Nguyen and Guido Marcucci
    Citation: Journal of Hematology & Oncology 2025 18:16
    Content type: Correspondence Published on:

  42. Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carc...

    Authors: Gang Chen, Dong-Chen Sun, Yi Ba, Ya-Xiong Zhang, Ting Zhou, Yuan-Yuan Zhao, Hong-Yun Zhao, Wen-Feng Fang, Yan Huang, Zhen Wang, Chao Deng, De-Sheng Hu, Wei Wang, Jin-Guan Lin, Gui-Ling Li, Su-Xia Luo…
    Citation: Journal of Hematology & Oncology 2025 18:15
    Content type: Research Published on:

  43. Small cell lung cancer (SCLC) is an aggressive and heterogeneous subtype, representing 15% of lung cancer cases. Although SCLC initially responds to etoposide and platinum (EP) chemotherapy, nearly all patient...

    Authors: Seungyeul Yoo, Ayushi S. Patel, Sarah Karam, Yi Zhong, Li Wang, Feng Jiang, Ranran Kong, Sharon Bikvan, Wenhui Wang, Abhilasha Sinha, Charles A. Powell, Jun Zhu and Hideo Watanabe
    Citation: Journal of Hematology & Oncology 2025 18:14
    Content type: Correspondence Published on:

  45. N7-methylguanosine (m7G) is an important RNA modification involved in epigenetic regulation that is commonly observed in both prokaryotic and eukaryotic organisms. Their influence on the synthesis and processi...

    Authors: Qihui Wu, Xiaodan Fu, Guoqian Liu, Xiaoyun He, Yimin Li and Chunlin Ou
    Citation: Journal of Hematology & Oncology 2025 18:12
    Content type: Review Published on:

  46. Authors: Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger…
    Citation: Journal of Hematology & Oncology 2025 18:11
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2024 17:128

  48. Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity,...

    Authors: Zwi N. Berneman, Maxime De Laere, Paul Germonpré, Manon T. Huizing, Yannick Willemen, Eva Lion, Hans De Reu, Jolien Van den Bossche, Jan Van den Brande, Pol Specenier, Sevilay Altintas, Peter A. van Dam, Nathalie Cools, Griet Nijs, Barbara Stein, Kim Caluwaerts…
    Citation: Journal of Hematology & Oncology 2025 18:9
    Content type: Correspondence Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2025 18:34

  49. Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral repl...

    Authors: Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci…
    Citation: Journal of Hematology & Oncology 2025 18:1
    Content type: Research Published on:

  50. Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging thera...

    Authors: Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg…
    Citation: Journal of Hematology & Oncology 2025 18:8
    Content type: Correspondence Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.9
    5-year Journal Impact Factor: 27.1
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2024
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 61

    Usage 2024
    Downloads: 3,430,659
    Altmetric mentions: 1,308

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us